Pediatric Targeted Therapy denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for pediatric targeted therapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied This Claim — and Why You Can Appeal

A non-formulary denial from BCBS for a pediatric targeted therapy means the prescribed agent is not on your plan's approved drug list at a covered tier. Non-formulary denials are not the end of the road — virtually all plans must offer a formulary exception process, and BCBS plans in particular must provide a medical exception pathway. The exception is typically granted when there is no formulary alternative that is clinically appropriate for the specific patient, or when formulary alternatives have been tried and failed, are contraindicated per the prescriber's clinical judgment, or are otherwise not suitable for this child's case.

## Your Federal Appeal Rights

• Formulary exception request: Submit a formulary exception request concurrently with or before the formal appeal. This is a distinct process from the grievance/appeal process and is sometimes faster.
• Internal appeal (ERISA §503 / ACA §2719): File a written internal appeal within the deadline on your denial notice. Denial of a formulary exception is itself an adverse benefit determination subject to full-and-fair review.
• External review (ACA §2719): After final internal denial, file with an IRO within approximately four months. External reviewers assess whether the exception denial was clinically appropriate.
• Expedited option: Available when standard timelines would seriously jeopardize the child's health. Expedited decisions are typically required within 72 hours.

## Documentation to Gather

1. Formulary exception form — complete BCBS's formulary exception form (request it from BCBS or your plan's pharmacy benefit manager). Attach the prescriber's letter and clinical documentation as exhibits. 2. Prescriber's medical-necessity letter — the treating pediatric specialist should explain why formulary alternatives are clinically inappropriate for this child, addressing each alternative on the formulary by name and explaining the clinical basis for its inadequacy. 3. Diagnosis and molecular documentation — if the therapy targets a specific mutation or biomarker, show that the child's confirmed profile matches the prescribed agent's labeled indication, and that formulary alternatives do not share that target. 4. Prior treatment history — documented trials of any formulary alternatives, with dates, outcomes, and reasons for discontinuation, if applicable. 5. FDA prescribing label — confirms the labeled indication and supports the argument that no formulary alternative covers the same indication for this diagnosis.

## Criteria-Mapping Structure for Your Appeal Letter

| Formulary-exception criterion | Supporting documentation | |---|---| | No formulary alternative is clinically appropriate | Prescriber's letter + molecular/biomarker documentation | | Formulary alternatives tried and failed | Medication history with dated chart notes | | Formulary alternative clinically contraindicated | Prescriber's clinical explanation (no specific numbers needed) | | Unique indication not covered by alternatives | FDA label comparison |

If the formulary exception is denied and the internal appeal is also denied, the external IRO will evaluate whether BCBS's formulary design results in a denial of medically necessary care — a strong basis for reversal in pediatric specialty cases.